Vesilute
Also known as: Peptídeo imune
Molecular Identifiers
Overview
Immunological bioregulatory tripeptide developed by the Khavinson group. Modulates gene expression in immune cells and regulates leukocyte function. Used in short cycles for immune modulation and support of the body's defense.
KED Lys-Glu-Asp Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Immune modulation and regulation of immune response
- Regulation of leukocyte function and activity
- Normalization of cytokine and immune mediator production
- Support for immunosurveillance and defense against pathogens
- Bioregulatory effect on cellular and humoral immune system
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day via subcutaneous injection |
| Frequency | Once daily |
| Timing | Morning or as per protocol |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Presentations & Preparation
Vials of Vesilute found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily